BW A868C is a hydantoin compound structurally related to the DP agonist BW245C. BW A868C antagonizes prosaglandin D2 and BW245C-induced activation of human platelet adenylate cyclase. Has been shown to antagonize accumulation of cAMP in rabbit non-pigmented ciliary epithelial cells. Shows virtually no effect on human TP, IP, EP1, EP2, and FP receptors. Ki is approximately 1.7 nM.
1 Caldwell, A.G., Harris, C.J., Stepney, R., et al. Hydantoin prostaglandin analogues, potent and selective inhibitors of platelet aggregation. J Chem Soc , Chem Commun (1979). 2 Trist, D.G., Collins, B.A., Wood, J., et al. The antagonism by BW A868C of PGD2 and BW245C activation of human platelet adenylate cyclase. Br J Pharmacol 96 301-306 (1989). 3 Bhattacherjee, P., Jacobs, N., Coca-Prados, M., et al. Identification of prostanoid receptors in rabbit non-pigmented ciliary epithelial cells. Exp Eye Res 62 491-498 (1996). 4 Giles, H., Leff, P., Bolofo, M.L., et al. The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist. Br J Pharmacol 96 291-300 (1989).
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.